Trial reportIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2013
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized study.
Trial report in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020.The Korean journal of internal medicine · 2021Guideline
- Evidence-Based Guidelines for the Treatment ofGut and liver · 2021Guideline
- Sequential versus standard triple first-line therapy for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2016Pooled it
- Comparison of the efficacies of triple, quadruple and sequential antibiotic therapy in eradicating Helicobacter pylori infection: A randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Trial
- Ten-day concomitant and sequential therapy for Helicobacter pylori effective in region with high antibiotic resistance rates.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2022Trial
- Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Trial
- Trial
- Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2015Trial
- Utility of commercially available triple drug regimen kits and addition of Lactobacillus reuteri in Helicobacter pylori eradication.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Article
- Sequential versus Standard Triple Therapy for First-LineAntibiotics (Basel, Switzerland) · 2024Review
- Choosing optimum regimen for treating Helicobacter pylori infection: Regional data may be the quintessential guide.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Article
- Clarithromycin versus Gemifloxacin in Quadruple Therapeutic Regimens forMiddle East journal of digestive diseases · 2017Article
- Antibiotic treatment for Helicobacter pylori: Is the end coming?World journal of gastrointestinal pharmacology and therapeutics · 2015Review
- Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.Middle East journal of digestive diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance has decreased eradication rates for Helicobacter pylori infection worldwide. A sequential treatment schedule has been reported to be effective, but studies published to date were performed in Italy. We undertook this study to determine whether these results could be replicated in India.
methodsA randomized, open-labeled, prospective controlled trial comparing sequential vs. standard triple-drug therapy was carried out at Lokmanya Tilak Municipal General Hospital, Mumbai. Two hundred and thirty-one patients with dyspepsia were randomized to a 10-day sequential regimen (40 mg of pantoprazole, 1 g of amoxicillin, each administered twice daily for the first 5 days, followed by 40 mg of pantoprazole, 500 mg of clarithromycin, and 500 mg of tinidazole, each administered twice daily for the remaining 5 days) or to standard 14-day therapy (40 mg of pantoprazole, 500 mg of clarithromycin, and 1 g of amoxicillin, each administered twice daily).
resultsThe eradication rate achieved with the sequential regimen was significantly greater than that obtained with the triple therapy. Per-protocol eradication rate of sequential therapy was 92.4% (95% CI 85.8-96.1%) vs. 81.8% (95% CI 73.9-87.8%) (p = 0.027) for standard drug therapy. Intention-to-treat eradication rates were 88.2% (95% CI 80.9-93.0%) vs. 79.1% (95% CI 71.1-85.4%), p = 0.029, respectively. The incidence of major and minor side effects between therapy groups was not significantly different (14.6% in the triple therapy group vs. 23.5% in sequential group, p = 0.12). Follow up was incomplete in 3.3% and 4.7% patients in standard and sequential therapy groups, respectively. Sequential therapy includes one additional antibiotic (tinidazole) that is not contained in standard therapy.
conclusionsSequential therapy was significantly better than standard therapy for eradicating H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.